With this new 2000L SUB, the Berkeley facility has tripled capacity over the last three years, and now offers cell culture manufacturing in scales from 100L to 3000L, with both SUBs and stainless steel bioreactors. In addition to cGMP manufacturing, the facility provides cell bank manufacturing and storage.
While focused on early-phase, the Berkeley facility operates within the global AGC Biologics integrated platform, with support from each AGC Biologics site. This structure is designed to create a seamless transition from early-phase through commercial production.
"We've carefully assembled an experienced team that is tuned in to the unique needs of customers within the critical early-phase development stage," said Vy Nguyen, site head of AGC Biologics, Berkeley. "We continue to expand capacity and capabilities to meet the diverse requisites within the early-phase manufacturing arena, and we value the opportunity to support companies developing tomorrow's breakthrough treatments."